{"url_path":"/sec/dwtx/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-060747-index.html","accession_number":"0001104659-26-060747","cik":"0001818844","ticker":"DWTX","issuer_name":"Dogwood Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-060747-index.html","primary_entity_key":"0001818844","primary_entity_name":"Dogwood Therapeutics, Inc."},"word_count":133,"has_tables":true,"body_markdown":"**Item 2.02 Results of Operations and Financial Condition.**\n\nOn May 14, 2026, Dogwood Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the first quarter ended March 31, 2026. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference into this Item 2.02.\n\nThe information provided pursuant to this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.\n\n​"}